Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
A dual-drug combination achieves broader cardiometabolic improvements beyond weight loss alone in people with obesity.
CagriSema is a novel combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 RA) evaluated in the pivotal REDEFINE 1 Phase 3 trial; this secondary analysis examines granular anthropometric and cardiometabolic endpoints. The findings characterize the breadth of cardiometabolic benefits achievable with this next-generation combination approach, potentially supporting regulatory and prescribing decisions beyond weight reduction alone.
What the study was
- Study design
- Secondary post-hoc analysis of Phase 3 RCT
- Population
- Adults with overweight/obesity enrolled in REDEFINE 1 Phase 3 trial
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
CagriSema represents the next evolution beyond semaglutide monotherapy for obesity/cardiometabolic risk. Phase 3 secondary analysis from REDEFINE 1 published in high-quality journal. The dual amylin+GLP-1 mechanism addresses a major unmet need for patients not achieving cardiometabolic targets on GLP-1 RAs alone.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.